Amgen (AMGN) Confirms FDA Approves LUMAKRAS (Sotorasib) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of.
Amgen To Present At The 2021 Jefferies Healthcare Conference prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Amgen To Present At The Cowen 2nd Annual Virtual Oncology Innovation Summit
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday, May 21, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen s business given at certain investor and medical conferences, can be accessed on Amgen s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen s Investor Relations Events Calendar. The webcast will be archived and ava
Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021
LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer
New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4-8, 2021.
Overall survival (OS) data from the Phase 2 CodeBreaK 100 trial of LUMAKRAS™ (sotorasib), a potentially first-in-class KRAS